

Felzartamab

Cat. No.:	HY-P99616
CAS No.:	2197112-39-1
Target:	CD38
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research ^[1] [2].
In Vitro	The MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	MOR202 can reduce osteolysis dose-dependently by up to 55% at 12 mg/kg. Co-administration with 0.6 mg/kg BOR or 50 mg/kg LEN at a low dose of 3 mg/kg completely eliminates osteolysis in mice MM model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. J. Endell, et al. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma. Meeting Abstract | 2011 ASCO Annual Meeting |

[2]. Marc S Raab, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020 May;7(5):e381-e394.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA